DIVISLAB's weekly return of -2.14% was in line with its peers, with a relatively lower volatility of 18.67%. The stock's Sharpe Ratio of -0.45 indicates a poor risk-adjusted return. Compared to its peers, DIVISLAB underperformed SUNPHARMA but outperformed DRREDDY and CIPLA. The stock's Max Drawdown of -2.23% suggests a moderate level of risk this week.

[Volatility: 18.67%]